Table 29Strength of evidence for cardiovascular drugs with or without magnesium—Intermediate outcomes

Cardiovascular Drug(s)/OutcomeRisk of BiasConsistencyDirectnessPrecisionGradeConclusion Treatment Effect*
MD (95% CI)
Hydrochlorothiazide
Blood pressure (mm Hg)ModerateConsistentIndirect (surrogate)ImpreciseInsufficientInconclusive
Systolic
Supine: Pooled
−4.54 (−13.25, 4.16)
Standing:
0 (−5.94, 5.94)
Diastolic
Supine: Pooled
−3.37 (−11.55, 4.81)
Standing:
1.00 (−8.84, 10.84)
Triglycerides (mg/dL)ModerateNAIndirect (surrogate)ImpreciseInsufficientInconclusive
1.77 (−103.19, 106.73)
Beta-adrenergic antagonists
Blood pressure (mm Hg)ModerateNAIndirect (surrogate)ImpreciseInsufficientInconclusive
Systolic
Supine:
−4.26 (−12.56, 4.04)
Standing:
−4.34 (−13.90, 5.22)
Diastolic
Supine:
−2.65 (−6.85, 1.55)
Standing:
−1.65 (−6.18, 2.88)

Note:

*

Range is provided when more than one study is being summarized; pooled data is from meta-analysis of more than one study.

Abbreviations: CI = confidence interval; MD = mean difference; mm Hg = millimetres of mercury; NA = not applicable.

From: Results

Cover of Dietary Supplements in Adults Taking Cardiovascular Drugs
Dietary Supplements in Adults Taking Cardiovascular Drugs [Internet].
Comparative Effectiveness Reviews, No. 51.
Seely D, Kanji S, Yazdi F, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.